Working… Menu

Gut Microbial Transplantation in Pediatric Inflammatory Bowel Diseases (GMT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01560819
Recruitment Status : Completed
First Posted : March 22, 2012
Results First Posted : December 4, 2013
Last Update Posted : December 30, 2013
Information provided by (Responsible Party):
Spectrum Health Hospitals

Brief Summary:

Inflammatory bowel disease (IBD) is a chronic, debilitating, relapsing inflammatory disorder affecting the gastrointestinal tract which does not have a medical cure. IBD consists of 2 different forms: Crohn's Disease (CD) and Ulcerative Colitis (UC). In the last 2 decades, Gut Microbial Transplantation (GMT), also known as fecal transplantation, has been used as a treatment option for Clostridium difficile colitis and UC. The literature supports strong evidence for the plausibility of using GMT for patients with IBD associated colitis, especially for patients with UC.

This research will be conducted in the Helen DeVos Children's Hospital (HDVCH) Pediatric gastrointestinal outpatient clinic. A pilot study of ten patients will be conducted to evaluate if GMT improves clinical symptoms in patients with IBD. Patients with IBD colitis (UC and CD with colonic involvement only) will be approached for GMT as a treatment option for their disease. Each subject will undergo 5 sessions (1 session/day, and not necessarily on consecutive days) of GMT within a period of 10 days. Post treatment evaluation will be done at their regularly scheduled clinic follow up.

Healthy donors >18 years of age will be chosen by the family, inclusive of immediate family members and friends. Donors will be required to complete a screening questionnaire, provide medical history, and undergo blood and stool tests.

Condition or disease Intervention/treatment Phase
Inflammatory Bowel Disease (IBD) Drug: Gut Microbial Transplantation Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Gut Microbial Transplantation in Pediatric Inflammatory Bowel Diseases
Study Start Date : March 2012
Actual Primary Completion Date : December 2012
Actual Study Completion Date : June 2013

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Study Participants
Participants did not receive any bowel preparation before Gut Microbial Transplantation (GMT). Audio-visual aids were used to help reduce participants' anxiety about GMT.
Drug: Gut Microbial Transplantation
Each participant received Gut Microbial Transplantation (GMT) as retention enema over a period of 1 hour (60mL enema every 15 minutes) daily for 5 days. Although 240mL of GMT solution was prepared for each participant, the final administered dose was dependent on the subject's comfort and willingness to proceed with the next enema, which was assessed after each enema infusion. Subjects were monitored for 30 minutes after GMT for any immediate adverse events and discharged.
Other Name: GMT

Primary Outcome Measures :
  1. Clinical Response [ Time Frame: 4 weeks following GMT Treatment ]
    Clinical response (i.e. improvement in Pediatric Ulcerative Colitis Activity Index (PUCAI) score by greater than or equal to 15 points from baseline) at 4 weeks following GMT treatment

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   7 Years to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Participant Inclusion Criteria:

  1. Children ages >7 and ≤21 years of age with established diagnosis of Inflammatory Bowel Disease (IBD) colitis (patient with ulcerative colitis (UC) or patients with crohn's disease (CD) with colonic involvement only)
  2. Have clinical disease (mild to moderate disease: 10≤ Pediatric Ulcerative Colitis Activity Index (PUCAI) <65)
  3. Have stable disease activity and therapy for two months prior to Gut Microbial Transplantation (GMT) procedure.

Participant Exclusion Criteria:

  1. Fulminant colitis
  2. Indication or scheduled for surgery
  3. Pregnancy
  4. Use of probiotic supplements during the study period (subjects who have stopped use of probiotic supplements will be eligible as long as they stop taking it 2 weeks prior to Day 1 of GMT)
  5. anemia (hemoglobin < 6.0 g/dL) in last one month
  6. Graft versus host disease (GVHD)
  7. Severely immunocompromised - defined as

    1. History of opportunistic infection (tuberculosis, Pneumocystis jirovecii or systemic fungal infections) in last one year or
    2. Neutropenia: Absolute neutrophil count (ANC) <500
  8. Major intra-abdominal surgery within 90 days prior to Day 1 of GMT
  9. Administration of any investigational drug within 30 days prior to Day 1 of GMT.
  10. Have received infliximab or other tumor necrosis factor (TNF) inhibitors within 2 months prior to Day 1 of GMT or are expected to receive such therapy within 1 month post final GMT.

Donor Inclusion Criteria

  1. Based on patient's and parents'/guardian's decision
  2. Will be chosen from immediate adult (≥18 years) family members or close friends
  3. Should have negative or normal results on screening tests (as explained in donor exclusion criteria below)

Donor Exclusion Criteria (adopted from guidelines provided by American Association of Blood Bank Donor History Questionnaire and American Gastroenterological Association)

  1. Positive or abnormal screening test to include:

    1. Hepatitis A Immunoglobulin M (IgM) antibody
    2. Hepatitis B antibody panel suggestive of infection (HBc IgM, HBs Ag, HBs Ab)
    3. Hepatitis C antibody Level
    4. Cytomegalovirus (CMV) IgM antibody
    5. Ebstein Barr Virus (EBV) viral capsid antigen (VCA) IgM antibody
    6. Syphilis Immunoglobulin G (IgG) Ab Screen
    7. Human Immune Deficiency Virus (HIV) I & II enzyme-linked immunosorbent assay (ELISA) screen
    8. Stool i) Fungal smear ii) Stool cultures to exclude Salmonella, Shigella, Escherichia Coli, Campylobacter, Yersinia, Vibrio, Listeria iii) Clostridium difficile toxin assay iv) Ova and parasite screen for Giardia and Cryptosporidium
  2. History of metabolic syndrome or gastric bypass surgery
  3. History of GI conditions: IBD, irritable bowel syndrome, chronic abdominal pain, GI Malignancy, blood in stool or diarrhea in the last 4 weeks before enrollment
  4. Antibiotic or probiotic use within 3 months before enrollment and for the duration of the donation
  5. Positive response on screening questionnaire to any of the following:

    1. History of active malignancy or any cancer within the last 5 years (excluding basal cell carcinoma of the skin)
    2. Family history of Creutzfeld-Jacob disease
    3. Corneal or dural transplant
    4. History of high risk sexual behavior (e.g. sexual contact with HIV/acquired immune deficiency syndrome (AIDS) positive, hepatitis positive partner, men who have sex with men, sex for drugs or money)
    5. History of signs of sexually transmitted infections such as genital ulcerations, anogenital herpes, anogenital warts, cancroids or syphilitic lesions
    6. Use of illicit drugs
    7. Travel within the last 6 months to areas of the world where diarrheal illnesses are endemic
    8. History or signs of immunosuppression i) History of any immunosuppressant medication(s) within the last 6 months or history of opportunistic infection(s) in past 1 year ii) Signs of immunosuppression such as:
    1. Oral thrush
    2. Disseminated lymphadenopathy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01560819

Layout table for location information
United States, Michigan
Helen DeVos Children's Hospital of Spectrum Health Hospitals
Grand Rapids, Michigan, United States, 49503
Sponsors and Collaborators
Spectrum Health Hospitals
Layout table for investigator information
Principal Investigator: Sachin Kunde, MD, MPH Helen DeVos Children's Hospital of Spectrum Health Hospitals
Publications of Results:
Layout table for additonal information
Responsible Party: Spectrum Health Hospitals Identifier: NCT01560819    
Other Study ID Numbers: 2011-233
First Posted: March 22, 2012    Key Record Dates
Results First Posted: December 4, 2013
Last Update Posted: December 30, 2013
Last Verified: December 2013
Keywords provided by Spectrum Health Hospitals:
ulcerative colitis, gut microbial transplantation
Additional relevant MeSH terms:
Layout table for MeSH terms
Intestinal Diseases
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases